- Home
- WOR vs KNSA Comparison
WOR vs KNSA Comparison
Compare WOR & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WOR
- KNSA
- Stock Information
- Founded
- WOR 1955
- KNSA 2015
- Country
- WOR United States
- KNSA United Kingdom
- Employees
- WOR N/A
- KNSA N/A
- Industry
- WOR Aerospace
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- WOR Consumer Discretionary
- KNSA Health Care
- Exchange
- WOR Nasdaq
- KNSA Nasdaq
- Market Cap
- WOR 2.7B
- KNSA 2.6B
- IPO Year
- WOR N/A
- KNSA 2018
- Fundamental
- Price
- WOR $56.35
- KNSA $38.51
- Analyst Decision
- WOR Buy
- KNSA Strong Buy
- Analyst Count
- WOR 3
- KNSA 7
- Target Price
- WOR $61.00
- KNSA $44.00
- AVG Volume (30 Days)
- WOR 378.3K
- KNSA 392.4K
- Earning Date
- WOR 09-23-2025
- KNSA 10-28-2025
- Dividend Yield
- WOR 1.21%
- KNSA N/A
- EPS Growth
- WOR 179.34
- KNSA N/A
- EPS
- WOR 2.14
- KNSA 0.07
- Revenue
- WOR $1,200,161,000.00
- KNSA $529,332,000.00
- Revenue This Year
- WOR $14.93
- KNSA $37.21
- Revenue Next Year
- WOR $4.45
- KNSA $12.07
- P/E Ratio
- WOR $26.36
- KNSA $582.26
- Revenue Growth
- WOR 0.76
- KNSA 56.18
- 52 Week Low
- WOR $37.88
- KNSA $17.82
- 52 Week High
- WOR $70.91
- KNSA $39.12
- Technical
- Relative Strength Index (RSI)
- WOR 36.07
- KNSA 64.65
- Support Level
- WOR $54.65
- KNSA $37.69
- Resistance Level
- WOR $56.63
- KNSA $38.83
- Average True Range (ATR)
- WOR 1.49
- KNSA 0.95
- MACD
- WOR -0.07
- KNSA 0.00
- Stochastic Oscillator
- WOR 42.28
- KNSA 79.11
About WOR Worthington Enterprises Inc.
Worthington Enterprises Inc is a designer and manufacturer of products and services, including manufactured metal products. The company operates under two reportable operating segments: Consumer Products and Building Products. The consumer Products business has a diverse product offering in the tools, outdoor living and celebrations categories, including propane-filled cylinders for torches, handheld torches, specialized hand tools, drywall tools, accessories and gas grills, and others. And the Building Products business engaged in providing pressurized containment solutions, providing critical components in the residential, non-residential, and repair and remodel end markets through essential categories. The company derives majority of the revenue from Building Products segment.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.